Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19665221 | 0.89 | HPGD (1.00) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL20570670 | 0.79 | HPGD (0.79) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL20570795 | 0.78 | HPGD (0.77) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL20570559 | 0.77 | HPGD (0.76) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL13946588 | 0.76 | ERBB2 (0.50) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL20571330 | 0.75 | ALDH1A1 (0.72) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL17550148 | 0.75 | HPGD (0.71) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL16772515 | 0.74 | MEN1 (0.80) | HPGDALDH1A1MEN1KMT2APOLB | |
| SCHEMBL16772576 | 0.74 | RXFP1 (0.95) | HPGDALDH1A1CYP1A2CYP2C9MEN1 | |
| SCHEMBL5809667 | 0.74 | HPGD (0.70) | HPGDALDH1A1CYP1A2CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464647-B1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2464647-B1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2016-09-21 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2464647-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019780-A1 | AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | HPGD 4271/4885ALDH1A1 2841/4885CYP1A2 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.